U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07335796) titled 'A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer' on Jan. 09.
Brief Summary: The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
Study Start Date: Jan. 09
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: BMS-986165
BMS986365 (CC-94676) is an androgen receptor (AR) ligand-directed degrader that was designed to target the AR for degradation in...